Fukun Guo, PhD

Member, Division of Experimental Hematology & Cancer Biology
Professor, UC Department of Pediatrics

fukun.guo@cchmc.org

About

Biography

I joined Cincinnati Children’s Hospital Medical Center in 2002 after training as a molecular and cellular biologist. I have an extensive background and long-term interest in immunology. Currently, I investigate the role and mechanisms of Rho family GTPases in T lymphocyte development and function.

Since beginning my work, I helped discover the role of Rho GTPases in T lymphocyte metabolism, which is important for T lymphocyte-mediated autoimmunity and allergy. Also, I helped determine the role of Rho family GTPases in anti-tumor T cell immunity.

My research has consistently been supported by National Institutes of Health (NIH) awards. I am also a reviewer of NIH grants for others’ research projects.

Services and Specialties

Interests

Rho GTPases and T and B lymphocyte development and function

Research Areas

Cancer and Blood Diseases

Publications

Interfacing biological neural networks with three-dimensional devices. Cai, H; Tian, C; Mackie, K; Guo, F. Nature Electronics. 2026; 9(5):461-462.

Organoid Brain-Machine-Interface Devices for Central Nervous System Repair. Xing, Y; Yang, Y; Hong, Z; Tian, C; Chu, H; Prokop, SC; Cai, H; Gu, M; Tchieu, J; Mackie, K; Guo, F. Advanced Science. 2026; e75444.

Abstract B013: Targeting CDC42 increases TCF1-mediated “stemness” and rejuvenates human T cells to enhance CAR-T efficacy. Cai, M; Duan, X; Jorgensen, R; Wunderlich, M; Guo, F; Zheng, Y. Cancer immunology research. 2026; 14(2_Supplement):b013-b013.

In vivo expression of CD3/CD19 bispecific T-cell engager and α-PD-L1-Fc enables effective and durable immunotherapy for CD19+/PD-L1+ leukemia. Yang, Y; Liu, X; Wei, J; Qin, J; Tan, Q; Ji, J; Guo, F; Zheng, Y; Bi, F; Liu, M; Wang, G. Leukemia. 2026; 40(2):348-359.

Genetic and epigenetic regulation of Treg cells by autism-related CHD8 2064. Yang, J; Zheng, Y; Guo, F. Journal of Immunology. 2025; 214(Supplement_1).

Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor. Cai, M; Adam, M; Duan, X; Guo, F; Zheng, Y. Science Advances. 2025; 11(44):eaea1212.

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors. Li, W; Xu, M; Cheng, M; Wei, J; Zhu, L; Deng, Y; Guo, F; Bi, F; Liu, M. Cancer Medicine. 2025; 14(14):e71065.

Abstract 1596: Tumor-derived RAC1A159V gain-of-function mutation promotes an immunosuppressive tumor microenvironment and represses response to immune checkpoint inhibitors. Cai, M; Adam, M; Guo, F; Zheng, Y. Cancer Research. 2025; 85(8_Supplement_1):1596-1596.

Genetic and epigenetic regulation of Treg cell fitness by autism-related chromatin remodeler CHD8. Yang, J-Q; Wang, C; Nayak, RC; Kolla, M; Cai, M; Pujato, M; Zheng, Y; Lu, QR; Guo, F. Cellular & Molecular Biology Letters. 2025; 30(1):36.

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Wei, J; Li, W; Zhang, P; Guo, F; Liu, M. Molecular Cancer. 2024; 23(1):279.